Clinical Trial Update: Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is testing KRT-232 (AMG-232) in combination with Decitabine and Venetoclax for Acute Myeloid Leukemia. The study is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• KRT-232
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING